載入...
Ziprasidone for Schizophrenia and Bipolar Disorder: A Review of the Clinical Trials
Ziprasidone is a newer “atypical” or “second‐generation” antipsychotic. Oral ziprasidone (ziprasidone hydrochloride) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia, and acute manic or mixed episodes associated with bipolar disorder (with or without psyc...
Na minha lista:
| 發表在: | CNS Drug Rev |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Blackwell Publishing Inc
2007
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6494156/ https://ncbi.nlm.nih.gov/pubmed/17627670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1527-3458.2007.00008.x |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|